NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma

Expert Opinion on Drug Delivery

Volumn 11, Issue 9, 2014, Pages 1497-1506

  Corradi, Massimo ^a   Chrystyn, Henry ^b   Cosio, Borja G ^c   Pirozynski, Michal ^d   Loukides, Stelios ^e   Louis, Renaud ^f   Spinola, Monica ^g   Usmani, Omar S ^h  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g CHIESI FARMACEUTICI S P A   (Italy)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Beclometasone; Dry powder inhaler; Extrafine particles; Formoterol; Small airways

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE; UNCLASSIFIED DRUG;

AEROSOL; AIRWAY; ASTHMA; DRUG EFFICACY; DRUG RELEASE; DRY POWDER INHALER; FLOW RATE; PARTICLE SIZE; PATIENT SATISFACTION; REVIEW;

ASTHMA; BECLOMETASONE; DRY POWDER INHALER; EXTRAFINE PARTICLES; FORMOTEROL; SMALL AIRWAYS;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; ETHANOLAMINES; HUMANS; LUNG; PARTICLE SIZE;

EID: 84906316409     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.928282     Document Type: Review

References (39)

1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404-6
2. Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med 2012;44:146-56
3. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: Direct measurement of intrabronchial pressure. J Appl Physiol 1992;72:1016-23
4. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95:703-19
5. Macklem PT. The physiology of small airways. Am J Respir Crit Care Med 1998;157:S181-3
6. Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010;80:120-6
7. Kaminsky DA, Irvin CG, Gurka DA, et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995;152:1784-90
8. Kraft M, Djukanovic R, Torvik J, et al. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 1995 107 162S
9. Kraft M, Djukanovic R, Torvik J, et al. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 1995;107:162S 9. Anderson WJ, Zajda E, Lipworth BJ. Are we overlooking persistent small airways. dysfunction in community-managed asthma?. Ann Allergy Asthma Immunol 2012;109(3):185-9
10. Perez T, Chanez P, Dusser D, et al. Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. Respir Med 2013;107:1667-74
11. Yamaguchi M, Niimi A, Ueda T, et al. Effect of inhaled corticosteroids on small airways in asthma: Investigation using impulse oscillometry. Pulm Pharmacol Ther 2009;22:326-32
12. Farah CS, King GG, Brown NJ, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 2012;129:381-7
13. Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: Major challenges for pulmonary drug delivery. Expert Opin Drug Deliv 2014;11(3):365-78
14. Hesselink AE, Penninx BW, Wijnhoven HA, et al. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scan J Prim Health Care 2001;19:255-60
15. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986;41:118-24
16. Goren A, Noviski N, Avital A, et al. Assessment of the ability of young children to use a powder inhaler device (Turbuhaler). Pediatr Pulmonol 1994;18:77-80
17. Bryant L, Bang C, Chew C, et al. Adequacy of inhaler technique used by people with asthma or chronic obstructive pulmonary disease. J Prim Health Care 2013;5:191-8
18. Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Respir Care 2005;50:1360-74
19. Ninane V, Brusselle GG, Louis R, et al. Usage of inhalation Devices in asthma and chronic obstructive pulmonary disease: A Delphi consensus statement. Expert Opin Drug Deliv 2014;11:313-23
20. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
21. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-Agonist particle size. Am J Respir Crit Care Med 2005;172:1497-504
22. Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012;108:195-200
23. Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 2001;95:720-7
24. Paggiaro P, Nicolini G, Papi A. Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. Expert Rev Respir Med 2008;2:161-6
25. Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations. J Asthma Allergy 2013;6:11-21
26. Dekhuijzen PN, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach. Respir Med 2013;107:1817-21
27. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31
28. Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metereddose inhaler, even at low flow rates. Chest 1995;115:952-6
29. Pasquali I, Brambilla G, Long E, et al. A visualization study for the aerosol generation in NEXThaler. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14-18; 2012;Chicago, Poster: M1150
30. Mariotti F, Sergio F, Acerbi D, et al. Lung deposition of the extra-fine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI- in healthy subjects, asthmatic and COPD patients. Presented at the European Respiratory Society 21st Annual Congress; 24 - 28 September 2011; Amsterdam, The Netherlands
31. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations. J Aerosol Med 2003;16:341-77
32. De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010;23:137-48
33. Sergio F, Francisco C, Muraro A, et al. Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy. Presented at the European Respiratory Society 22st Annual Congress; 1 - 5 September 2012; Vienna, Austria
34. Zuccaro F, Sergio F, Petruzzelli S, et al. Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients. Presented at the European Respiratory Society 20th Annual Congress 18-22 September 2010; Barcelona, Spain. Eur Respir J 2010;36(Suppl 54):829s
35. Scuri M, Alfieri V, Giorgio A, et al. Measurement of the inhalation profile through a novel dry powder inhaler (NEXThaler) in asthmatic patients using acoustic monitoring. Am J Respir Crit Care Med 2013;187:A1931
36. EMEA/CHMP/QWP/49313/2005corr. (2005): Committee For Medicinal Products For Human Use (CHMP). Guideline on the pharmaceutical quality of inhalation and nasal products
37. Price D, Thomas M, Mitchell G, Niziol C. Improvement of asthma control with a breath-Actuated pressurised metred dose inhaler (BAI): A prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-Actuated device. Respir Med 2003;97:12-19
38. Voshaar T, Spinola M, Linnane P, et al. Comparing usability of NEXThaler with other inhaled corticosteroid/long-Acting beta2-Agonist fixed combination Dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Deliv 2013; doi: 10.1089/jamp.2013.1086
39. Anderson P. Patient preference for and satisfaction of inhaler devices. Eur Respir Rev 2005;14:109-16.